

Medicare Drug Price Negotiation Program: Top 50 Negotiation-Eligible Drugs for Initial Price Applicability Year 2028



In accordance with Section 30.4 of the [Medicare Drug Price Negotiation Program: Final Guidance, Implementation of Sections 1191 – 1198 of the Social Security Act for Initial Price Applicability Year 2028 and Manufacturer Effectuation of the Maximum Fair Price in 2026, 2027, and 2028](#) (“Final Guidance”), CMS has published a list of 50 top negotiation-eligible drugs (inclusive of the 15 selected drugs) ranked by combined Total Expenditures under Part B and Part D, information on the National Drug Code (NDC)-9s NDC-11s, and Healthcare Common Procedure Coding System (HCPCS) codes for the negotiation-eligible drugs, as applicable.

Rank	Drug Name	Total Medicare Part B and Part D Prescription Drug Expenditures from November 2024-October 2025 ¹	NDC-9s	NDC-11s	HCPCS Code (if applicable) ²
1	TRULICITY	\$4,898,378,000	000021433, 000021434, 000022236, 000023182, 500903483, 500903484, 500905467, 500906453, 500906456, 500906571, 500907589	00002143301, 00002143361, 00002143380, 00002143401, 00002143461, 00002143480, 00002223601, 00002223661, 00002223680, 00002318201, 00002318261, 00002318280, 50090348300, 50090348400, 50090546700, 50090645300, 50090645600, 50090657100, 50090758900	
2	BIKTARVY	\$3,904,486,000	500906247, 619582501, 619582505, 619582506, 705183080	50090624700, 61958250101, 61958250102, 61958250103, 61958250501, 61958250601, 70518308000, 70518308001, 70518308002, 70518308003	
3	ORENCIA	\$2,450,065,000	000032187, 000032188, 000032814, 000032818	00003218710, 00003218713, 00003218811, 00003218851, 00003218890, 00003218891, 00003281411, 00003281811	J0129
4	COSENTYX	\$2,327,442,000	000780639, 000781056, 000781070, 000781168	00078063941, 00078063968, 00078063997, 00078063998, 00078105697, 00078105699, 00078107068, 00078107096, 00078116861	J3247
5	ERLEADA	\$1,947,504,000	596760600, 596760604	59676060012, 59676060056, 59676060099, 59676060414, 59676060430	
6	KISQALI	\$1,578,679,000	000780860, 000780867, 000780874	00078086001, 00078086714, 00078086742, 00078087421, 00078087463	
7	ENTYVIO	\$1,483,348,000	647640107, 647640108, 647640300	64764010710, 64764010711, 64764010820, 64764010821, 64764030020	J3380

Rank	Drug Name	Total Medicare Part B and Part D Prescription Drug Expenditures from November 2024-October 2025 ¹	NDC-9s	NDC-11s	HCPCS Code (if applicable) ²
8	VERZENIO	\$1,428,714,000	000024483, 000024815, 000025337, 000026216	00002448354, 00002448362, 00002481554, 00002481562, 00002533754, 00002533762, 00002533763, 00002621654	
9	BOTOX; BOTOX COSMETIC*	\$1,143,070,000	000231145, 000233919, 000233921, 000239232	00023114501, 00023114502, 00023391950, 00023392102, 00023392103, 00023923201	J0585
10	LENVIMA	\$1,088,498,000	628560704, 628560708, 628560710, 628560712, 628560714, 628560718, 628560720, 628560724	62856070405, 62856070430, 62856070805, 62856070830, 62856071005, 62856071030, 62856071205, 62856071230, 62856071405, 62856071430, 62856071805, 62856071830, 62856072005, 62856072030, 62856072405, 62856072430	
11	XOLAIR	\$1,077,271,000	502420040, 502420214, 502420215, 502420227	50242004062, 50242004086, 50242021401, 50242021403, 50242021455, 50242021486, 50242021501, 50242021503, 50242021555, 50242021586, 50242022701, 50242022755, 50242022786, 50242022799	J2357
12	REXULTI	\$1,075,274,000	591480035, 591480036, 591480037, 591480038, 591480039, 591480040, 591480042, 591480044, 705183548	59148003513, 59148003607, 59148003613, 59148003707, 59148003713, 59148003807, 59148003813, 59148003907, 59148003913, 59148004007, 59148004013, 59148004207, 59148004414, 70518354800	
13	XELJANZ; XELJANZ XR	\$1,013,332,000	000690501, 000690502, 000691001, 000691002, 000691029, 635390012, 635390016, 635390501, 635390502	00069050114, 00069050130, 00069050230, 00069100101, 00069100102, 00069100103, 00069100201, 00069100202, 00069100203, 00069102901, 00069102902, 63539001202, 63539001602, 63539050114, 63539050130, 63539050230	
14	ANORO ELLIPTA	\$812,772,000	001730869, 669930134	00173086906, 00173086910, 00173086961, 66993013497	

Rank	Drug Name	Total Medicare Part B and Part D Prescription Drug Expenditures from November 2024-October 2025 ¹	NDC-9s	NDC-11s	HCPCS Code (if applicable) ²
15	CIMZIA	\$786,790,000	504740700, 504740710, 504740750	50474070061, 50474070062, 50474071079, 50474071080, 50474071081, 50474075010	J0717
16	LYNPARZA	\$783,215,000	003100569, 003100578, 003100668, 003100679	00310056912, 00310056960, 00310057812, 00310057860, 00310066812, 00310066860, 00310066895, 00310067912, 00310067960, 00310067995	
17	SIMPONI; SIMPONI ARIA	\$724,162,000	578940070, 578940071, 578940350	57894007001, 57894007002, 57894007089, 57894007090, 57894007101, 57894007102, 57894007189, 57894007190, 57894035001, 57894035089	J1602
18	EPCLUSA	\$625,676,000	619582201, 619582203, 619582204, 619582205, 726262701	61958220101, 61958220301, 61958220401, 61958220501, 72626270101	
19	TIVICAY; TIVICAY PD	\$623,264,000	497020226, 497020227, 497020228, 497020255, 530021810, 538081130, 672961818	49702022613, 49702022713, 49702022813, 49702025537, 53002181006, 53808113001, 67296181803, 67296181805, 67296181807	
20	SYNJARDY; SYNJARDY XR	\$603,479,000	005970159, 005970168, 005970175, 005970180, 005970280, 005970290, 005970295, 005970300	00597015918, 00597015960, 00597015966, 00597016818, 00597016860, 00597016866, 00597017518, 00597017560, 00597017566, 00597018018, 00597018060, 00597018066, 00597028036, 00597028073, 00597028090, 00597029020, 00597029059, 00597029074, 00597029561, 00597029578, 00597029588, 00597030020, 00597030045, 00597030093	
21	PERJETA	\$602,537,000	502420145	50242014501	J9306
22	STRIBILD; GENVOYA	\$549,687,000	500901318, 500902279, 538080887, 619581201, 619581901, 691891201, 705180568, 705180674	50090131800, 50090227900, 53808088701, 61958120101, 61958190101, 69189120101, 70518056800, 70518067400	

Rank	Drug Name	Total Medicare Part B and Part D Prescription Drug Expenditures from November 2024-October 2025 ¹	NDC-9s	NDC-11s	HCPCS Code (if applicable) ²
23	XIIDRA	\$539,591,000	000780911, 242080911, 540920606	00078091105, 00078091112, 00078091194, 00078091195, 24208091105, 24208091112, 24208091194, 24208091195, 54092060601, 54092060606	
24	BENLYSTA	\$526,742,000	494010088, 494010101, 494010102	49401008801, 49401008802, 49401008835, 49401008842, 49401008847, 49401008850, 49401008861, 49401010101, 49401010201	J0490
25	TRIUMEQ; TRIUMEQ PD	\$502,567,000	497020231, 497020258, 500901606, 545696569	49702023113, 49702025837, 50090160600, 54569656900	
26	INLYTA	\$483,240,000	000690145, 000690151, 635390026, 635390044	00069014501, 00069015111, 63539002601, 63539004401, 63539004402	
27	STIOLTO RESPIMAT	\$452,422,000	005970155	00597015528, 00597015531, 00597015561, 00597015570	
28	JULUCA	\$441,244,000	497020242	49702024213	
29	MULTAQ	\$431,994,000	000244142, 548683086, 551548104	00024414200, 00024414206, 00024414210, 00024414218, 00024414250, 00024414260, 54868308600, 55154810402, 55154810408	
30	SYMTUZA	\$431,451,000	596760800	59676080030, 59676080099	
31	TRINTELLIX	\$392,499,000	551540256, 551540257, 647640720, 647640730, 647640750, 705182642, 705184284, 705184483	55154025608, 55154025708, 64764072007, 64764072009, 64764072030, 64764072077, 64764072090, 64764073007, 64764073009, 64764073030, 64764073077, 64764073090, 64764075007, 64764075009, 64764075030, 64764075077, 64764075090, 70518264200, 70518264201, 70518428400, 70518428401, 70518448300, 70518448301	
32	TYSABRI	\$387,453,000	644060008	64406000801	J2323
33	ERBITUX	\$371,863,000	667330948, 667330958	66733094823, 66733095823	J9055
34	INCRUSE ELLIPTA	\$365,869,000	001730873	00173087306, 00173087310, 00173087361	
35	TYMLOS	\$359,131,000	705390001	70539000101, 70539000102, 70539000198, 70539000199	

Rank	Drug Name	Total Medicare Part B and Part D Prescription Drug Expenditures from November 2024-October 2025 ¹	NDC-9s	NDC-11s	HCPCS Code (if applicable) ²
36	COMBIVENT RESPIMAT	\$353,784,000	005970024	00597002402, 00597002458, 00597002459	
37	ARANESP	\$347,347,000	555130002, 555130003, 555130004, 555130005, 555130006, 555130021, 555130023, 555130025, 555130027, 555130028, 555130032, 555130057, 555130098, 555130111	55513000201, 55513000204, 55513000301, 55513000304, 55513000401, 55513000404, 55513000501, 55513000504, 55513000601, 55513000621, 55513002101, 55513002104, 55513002301, 55513002304, 55513002501, 55513002504, 55513002701, 55513002704, 55513002801, 55513003201, 55513005701, 55513005704, 55513009801, 55513009804, 55513011101	J0881
38	VECTIBIX	\$341,534,000	555130954, 555130956	55513095401, 55513095421, 55513095601, 55513095621	J9303
39	LOKELMA	\$337,495,000	003101105, 003101110, 500906501, 500906502	00310110501, 00310110530, 00310110539, 00310111001, 00310111030, 00310111039, 00310111091, 00310111093, 00310111094, 00310111098, 50090650100, 50090650101, 50090650200	

Rank	Drug Name	Total Medicare Part B and Part D Prescription Drug Expenditures from November 2024-October 2025 ¹	NDC-9s	NDC-11s	HCPCS Code (if applicable) ²
40	OXYCONTIN	\$336,022,000	000935731, 000935732, 000935733, 000935734, 001151556, 001151557, 001151558, 001151559, 001151560, 001151561, 001151562, 005912693, 005912708, 007815703, 007815726, 007815767, 007815785, 107020801, 107020803, 107020805, 317220109, 317220110, 317220111, 557000791, 590110410, 590110415, 590110420, 590110430, 590110440, 590110460, 590110480, 633040683, 633040684, 636293772, 636293774, 672961376, 672961560, 692382294, 692382296, 692382298, 692382300	00093573101, 00093573201, 00093573301, 00093573401, 00115155601, 00115155701, 00115155801, 00115155901, 00115156001, 00115156101, 00115156201, 00591269301, 00591270801, 00781570301, 00781572601, 00781576701, 00781578501, 10702080101, 10702080301, 10702080501, 31722010901, 31722011001, 31722011101, 55700079130, 59011041010, 59011041020, 59011041510, 59011041520, 59011042010, 59011042020, 59011043010, 59011043020, 59011044010, 59011044020, 59011046010, 59011046020, 59011048010, 59011048020, 63304068301, 63304068401, 63629377205, 63629377401, 63629377402, 63629377403, 67296137602, 67296156002, 69238229401, 69238229601, 69238229801, 69238230001	

Rank	Drug Name	Total Medicare Part B and Part D Prescription Drug Expenditures from November 2024-October 2025 ¹	NDC-9s	NDC-11s	HCPCS Code (if applicable) ²
41	RYTARY; CREXONT	\$308,098,000	608460661, 608460662, 608460663, 608460664, 648960661, 648960662, 648960663, 648960664, 648960967, 648960968, 648960969, 648960970, 707102139, 707102140, 707102141, 707102142	60846066101, 60846066201, 60846066301, 60846066401, 64896066101, 64896066109, 64896066143, 64896066199, 64896066201, 64896066209, 64896066243, 64896066299, 64896066301, 64896066309, 64896066343, 64896066399, 64896066401, 64896066443, 64896096716, 64896096723, 64896096816, 64896096823, 64896096916, 64896096923, 64896097016, 64896097023, 70710213901, 70710214001, 70710214101, 70710214201	
42	KADCYLA	\$306,051,000	502420087, 502420088	50242008701, 50242008801	J9354
43	CYRAMZA	\$299,282,000	000027669, 000027678	00002766901, 00002767801	J9308

Rank	Drug Name	Total Medicare Part B and Part D Prescription Drug Expenditures from November 2024-October 2025 ¹	NDC-9s	NDC-11s	HCPCS Code (if applicable) ²
44	FLOVENT DISKUS 50; FLOVENT DISKUS 100; FLOVENT DISKUS 250; FLOVENT HFA; ARNUITY ELLIPTA	\$294,823,000	001730600, 001730601, 001730602, 001730718, 001730719, 001730720, 001730874, 001730876, 001730888, 500900910, 500900916, 500900934, 500901245, 500906053, 500906055, 500906058, 500907076, 530021294, 530021310, 530021401, 530022294, 530022310, 548685362, 548685637, 548685995, 631870957, 669930078, 669930079, 669930080, 669930166, 669930167, 669930168, 669930790, 669930791, 669930792, 687886926, 687888762, 765191177	00173060000, 00173060001, 00173060002, 00173060100, 00173060101, 00173060102, 00173060200, 00173060201, 00173060202, 00173071820, 00173071860, 00173071920, 00173071961, 00173072020, 00173087410, 00173087414, 00173087461, 00173087610, 00173087614, 00173087661, 00173088810, 00173088862, 50090091000, 50090091600, 50090093400, 50090124500, 50090605300, 50090605500, 50090605800, 50090707600, 53002129401, 53002131001, 53002140101, 53002229401, 53002231001, 54868536200, 54868563700, 54868599500, 63187095760, 66993007896, 66993007996, 66993008096, 66993016697, 66993016797, 66993016897, 66993079097, 66993079197, 66993079297, 68788692601, 68788876201, 76519117700	
45	ARISTADA; ARISTADA INITIO KIT	\$279,926,000	657570401, 657570402, 657570403, 657570404, 657570500	65757040101, 65757040103, 65757040104, 65757040201, 65757040203, 65757040204, 65757040301, 65757040303, 65757040304, 65757040401, 65757040403, 65757040404, 65757050003, 65757050004	J1943, J1944
46	LONSURF	\$270,411,000	648421020, 648421025	64842102001, 64842102002, 64842102003, 64842102501, 64842102502, 64842102503	

Rank	Drug Name	Total Medicare Part B and Part D Prescription Drug Expenditures from November 2024-October 2025 ¹	NDC-9s	NDC-11s	HCPCS Code (if applicable) ²
47	BRIVIACT	\$253,641,000	504740370, 504740470, 504740570, 504740670, 504740770, 504740870, 504740970	50474037066, 50474047009, 50474047012, 50474047014, 50474047066, 50474057009, 50474057012, 50474057014, 50474057066, 50474067066, 50474077009, 50474077012, 50474077014, 50474077066, 50474087015, 50474097063, 50474097075	
48	PREZCOBIX	\$244,341,000	500901723, 596760575, 596760578	50090172300, 59676057530, 59676057830	
49	PURIFIED CORTROPHIN GEL	\$237,825,000	625590860, 625590861	62559086011, 62559086015, 62559086111, 62559086135	J0802
50	DOPTelet	\$236,862,000	713690010, 713690020	71369001030, 71369002010, 71369002011, 71369002015, 71369002016, 71369002030	

*The selected drug name reflects the manufacturer’s naming convention, and use of the manufacturer’s assigned name when describing the selected drug is not indicative of any change in Medicare coverage or payment for this selected drug when used for cosmetic purposes.

1. Numbers are rounded to the nearest thousands.
2. HCPCS codes shown are associated with the drug in the Part B fee-for-service claims or Medicare Advantage encounter data from the time period beginning November 1, 2024 and ending October 31, 2025.